Transgene SA (TRGNF)
USD 1.59
(0.0%)
USD 1.59
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.58 Million EUR | -11.49% |
| 2022 | -30.31 Million EUR | -83.16% |
| 2021 | -16.55 Million EUR | -16.32% |
| 2020 | -14.1 Million EUR | 8.09% |
| 2019 | -16.59 Million EUR | -243.18% |
| 2018 | -26 Million EUR | 136.71% |
| 2017 | -29.5 Million EUR | -40.75% |
| 2016 | -20.92 Million EUR | 23.01% |
| 2015 | -34.71 Million EUR | 30.27% |
| 2014 | -37.4 Million EUR | -1.76% |
| 2013 | -38.29 Million EUR | 2.62% |
| 2012 | -39.31 Million EUR | 6.56% |
| 2011 | -42.08 Million EUR | -30.74% |
| 2010 | -32.19 Million EUR | -36.55% |
| 2009 | -23.57 Million EUR | -28.89% |
| 2008 | -18.29 Million EUR | -255.3% |
| 2007 | -5.14 Million EUR | 75.4% |
| 2006 | -20.92 Million EUR | 0.0% |
| 2004 | -20.24 Million EUR | 0.24% |
| 2003 | -20.38 Million EUR | -7.64% |
| 2002 | -19.03 Million EUR | 4.16% |
| 2001 | -21.27 Million EUR | 14.02% |
| 2000 | -22.88 Million EUR | -15.07% |
| 1999 | -19.88 Million EUR | -29.01% |
| 1998 | -37.06 Million EUR | 3.64% |
| 1997 | -15.99 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.06 Million EUR | -19.85% |
| 2024 Q2 | -8.06 Million EUR | 0.0% |
| 2023 Q4 | -6.73 Million EUR | 0.0% |
| 2023 FY | - EUR | -11.49% |
| 2023 Q1 | -7.48 Million EUR | 57.2% |
| 2023 Q2 | -16.86 Million EUR | -125.17% |
| 2023 Q3 | -6.73 Million EUR | 60.07% |
| 2022 Q4 | -17.49 Million EUR | -146.1% |
| 2022 FY | - EUR | -83.16% |
| 2022 Q2 | -17.78 Million EUR | -154.19% |
| 2022 Q3 | -7.1 Million EUR | 60.03% |
| 2022 Q1 | -6.99 Million EUR | 39.7% |
| 2021 Q1 | -6.25 Million EUR | 58.66% |
| 2021 Q3 | -4.36 Million EUR | 72.97% |
| 2021 FY | - EUR | -16.32% |
| 2021 Q2 | -16.14 Million EUR | -158.06% |
| 2021 Q4 | -11.6 Million EUR | -165.88% |
| 2020 Q3 | -6.05 Million EUR | 56.78% |
| 2020 Q1 | -5.26 Million EUR | 62.92% |
| 2020 Q2 | -14.01 Million EUR | -166.17% |
| 2020 Q4 | -15.13 Million EUR | -149.94% |
| 2020 FY | - EUR | 8.09% |
| 2019 Q2 | -15.84 Million EUR | -157.17% |
| 2019 Q1 | -6.16 Million EUR | 9.56% |
| 2019 Q3 | -5.11 Million EUR | 67.72% |
| 2019 Q4 | -14.19 Million EUR | -177.56% |
| 2019 FY | - EUR | -243.18% |
| 2018 FY | - EUR | 136.71% |
| 2018 Q1 | -6.19 Million EUR | -19.01% |
| 2018 Q2 | -6.19 Million EUR | 0.0% |
| 2018 Q3 | -6.81 Million EUR | -10.02% |
| 2018 Q4 | -6.81 Million EUR | 0.0% |
| 2017 FY | - EUR | -40.75% |
| 2017 Q4 | -5.2 Million EUR | 0.0% |
| 2017 Q2 | -7.83 Million EUR | 0.0% |
| 2017 Q1 | -7.83 Million EUR | -46.18% |
| 2017 Q3 | -5.2 Million EUR | 33.6% |
| 2016 Q2 | -4.83 Million EUR | 0.0% |
| 2016 FY | - EUR | 23.01% |
| 2016 Q4 | -5.36 Million EUR | 0.0% |
| 2016 Q3 | -5.36 Million EUR | -10.93% |
| 2016 Q1 | -4.83 Million EUR | 22.06% |
| 2015 FY | - EUR | 30.27% |
| 2015 Q4 | -6.19 Million EUR | 0.0% |
| 2015 Q2 | -6.61 Million EUR | 0.0% |
| 2015 Q3 | -6.19 Million EUR | 6.24% |
| 2015 Q1 | -6.61 Million EUR | -3.15% |
| 2014 Q4 | -6.41 Million EUR | 0.0% |
| 2014 Q3 | -6.41 Million EUR | 31.0% |
| 2014 Q1 | -9.29 Million EUR | -6.61% |
| 2014 FY | - EUR | -1.76% |
| 2014 Q2 | -9.29 Million EUR | 0.0% |
| 2013 Q2 | -10.42 Million EUR | 0.0% |
| 2013 Q4 | -8.71 Million EUR | 0.0% |
| 2013 Q3 | -8.71 Million EUR | 16.37% |
| 2013 FY | - EUR | 2.62% |
| 2013 Q1 | -10.42 Million EUR | 0.0% |
| 2012 FY | - EUR | 6.56% |
| 2011 FY | - EUR | -30.74% |
| 2010 FY | - EUR | -36.55% |
| 2009 FY | - EUR | -28.89% |
| 2008 FY | - EUR | -255.3% |
| 2007 FY | - EUR | 75.4% |
| 2006 FY | - EUR | 0.0% |
| 2005 Q1 | 1.01 Million EUR | 104.32% |
| 2005 Q2 | -4.92 Million EUR | -585.69% |
| 2004 Q3 | 832.52 Thousand EUR | 115.85% |
| 2004 Q2 | -5.25 Million EUR | 6.69% |
| 2004 Q1 | -5.62 Million EUR | 14.74% |
| 2004 Q4 | -23.47 Million EUR | -2919.17% |
| 2004 FY | - EUR | 0.24% |
| 2003 Q2 | -5.4 Million EUR | -5.17% |
| 2003 FY | - EUR | -7.64% |
| 2003 Q3 | -4.59 Million EUR | 15.06% |
| 2003 Q1 | -5.14 Million EUR | -5.89% |
| 2003 Q4 | -6.6 Million EUR | -43.72% |
| 2002 Q2 | -5.21 Million EUR | 3.38% |
| 2002 FY | - EUR | 4.16% |
| 2002 Q1 | -5.4 Million EUR | 3.87% |
| 2002 Q3 | -4.85 Million EUR | 7.03% |
| 2002 Q4 | -4.85 Million EUR | -0.11% |
| 2001 Q2 | -5.99 Million EUR | -2.64% |
| 2001 FY | - EUR | 14.02% |
| 2001 Q4 | -5.61 Million EUR | -6.82% |
| 2001 Q3 | -5.25 Million EUR | 12.26% |
| 2001 Q1 | -5.83 Million EUR | -12.67% |
| 2000 Q1 | -7.07 Million EUR | 72.01% |
| 2000 FY | - EUR | -15.07% |
| 2000 Q4 | -5.18 Million EUR | 35.63% |
| 2000 Q3 | -8.05 Million EUR | -85.18% |
| 2000 Q2 | -4.34 Million EUR | 38.52% |
| 1999 Q1 | 1.48 Million EUR | 105.89% |
| 1999 FY | - EUR | -29.01% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1999 Q4 | -25.26 Million EUR | -3463.79% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1998 Q4 | -25.14 Million EUR | -5986.12% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 FY | - EUR | 3.64% |
| 1997 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 71.018% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -247.248% |
| SQZ Biotechnologies Company | -64.14 Million USD | 67.902% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -18.526% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 121.893% |
| Mesoblast Limited | -62.38 Million USD | 67.001% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1240.322% |
| Genus plc | 73.7 Million USD | 127.935% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -211.396% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -480.434% |
| Marizyme, Inc. | -34.28 Million USD | 39.944% |
| ContraFect Corporation | -64.99 Million USD | 68.326% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -134.701% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -354.863% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1368.675% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -678.537% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -785.955% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3874.164% |
| Accustem Sciences Inc. | -3.74 Million USD | -449.538% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 57.31% |
| EV Biologics, Inc. | -1.26 Million USD | -1524.772% |
| Q BioMed Inc. | -617.62 Thousand USD | -3233.398% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 676.372% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3155.504% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -801.208% |
| Biomind Labs Inc. | -1.03 Million USD | -1890.046% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 308.444% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -187.491% |
| Skye Bioscience, Inc. | -13.54 Million USD | -51.968% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1284.149% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -82252.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -430.028% |
| IMV Inc. | -35.52 Million USD | 42.044% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -29.731% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -722.874% |
| GB Sciences, Inc. | -1.41 Million USD | -1349.977% |
| Alpha Cognition Inc. | -9.7 Million USD | -112.125% |
| HST Global, Inc. | -5303.00 USD | -388133.076% |
| CSL Limited | 4.78 Billion USD | 100.43% |
| Halberd Corporation | -74.27 Thousand USD | -27617.121% |
| Enzolytics Inc. | -2.12 Million USD | -870.204% |
| Resverlogix Corp. | -11.74 Million USD | -75.336% |
| Affymax, Inc. | -14.29 Million USD | -44.022% |
| SYBLEU INC | -141.57 Thousand USD | -14442.526% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -572.148% |
| argenx SE | -216.02 Million USD | 90.47% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 62.797% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1791.701% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1273.535% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 5534.427% |
| AVAX Technologies, Inc. | -6.11 Million USD | -236.81% |
| Zenith Capital Corp. | -8.6 Million USD | -139.228% |
| Genscript Biotech Corporation | -248.71 Million USD | 91.722% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -118079.209% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -741.542% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -11596.108% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 48.058% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -611.815% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1867.673% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 306286.794% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1076.458% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -971.783% |
| BioStem Technologies, Inc. | -7.55 Million USD | -172.557% |
| ONE Bio Corp. | 13.61 Million USD | 251.237% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -11269.058% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -900.875% |
| Agentix Corp. | -1.37 Million USD | -1400.85% |
| LadRx Corporation | 412.28 Thousand USD | 5093.657% |
| Cell Source, Inc. | -4.27 Million USD | -381.87% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -5506.433% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1504.408% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -2097.345% |
| NovAccess Global Inc. | -1.03 Million USD | -1889.569% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 332.533% |
| Itoco Inc. | -1.86 Million USD | -1001.555% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -5323.318% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1744.803% |
| Kadimastem Ltd | -2.62 Million USD | -684.49% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -8508.823% |
| CytoDyn Inc. | -18.02 Million USD | -14.194% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -25951.196% |
| Mobile Lads Corp. | -2.24 Million USD | -818.632% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -168253.913% |
| Qrons Inc. | -40.08 Thousand USD | -51265.984% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -4139.023% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 4003.434% |
| Rebus Holdings, Inc. | -951 Thousand USD | -2064.879% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1838.588% |
| International Stem Cell Corporation | 202 Thousand USD | 10292.079% |
| Bioxytran, Inc. | -3.82 Million USD | -438.932% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -39010.942% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -736.254% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 42.602% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -45651.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -651.936% |
| Neutra Corp. | -181.24 Thousand USD | -11259.085% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -2.128% |
| PureTech Health plc | -11.62 Million USD | -77.071% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -2.135% |
| IXICO plc | -707 Thousand USD | -2812.023% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -167.899% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 57.415% |
| CSL Limited | 4.73 Billion USD | 100.435% |
| Cellectis S.A. | -92.63 Million USD | 77.775% |